Pyridopyrimidinones as a new chemotype of calcium dependent protein kinase 1 (CDPK1) inhibitors for Cryptosporidium
Elise Waldron-Young,Wissarut Wijitrmektong,Ryan Choi,Grant R. Whitman,Matthew A. Hulverson,Raheela Charania,Aidan Keelaghan,Li Li,Songpol Srinual,Sameer Nikhar,Case W. McNamara,Melissa S. Love,Lauren Huerta,Malina A. Bakowski,Ming Hu,Wesley C. Van Voorhis,Jan R. Mead,Gregory D. Cuny
DOI: https://doi.org/10.1016/j.molbiopara.2024.111637
IF: 1.845
2024-06-20
Molecular and Biochemical Parasitology
Abstract:The protozoan protein kinase calcium-dependent protein kinase 1 (CDPK1) has emerged as a potential therapeutic target for the treatment of cryptosporidiosis. A focused screen of known kinase inhibitors identified a pyridopyrimidinone as a new chemotype of Cryptosporidium parvum ( Cp ) CDPK1 inhibitors. Structural comparison of Cp CDPK1 to two representative human kinases, RIPK2 and Src, revealed differences in the positioning of the αC-helix that was used in the design of a potent pyridopyrimidinone-based Cp CDPK1 inhibitor 7 (a.k.a. UH15-16, IC 50 = 10 nM), which blocked the growth of three C. parvum strains (EC 50 = 12-40 nM) as well as C. hominis (EC 50 = 85 nM) in HCT-8 host cells. Pharmacokinetic and tissue distribution analyses indicated that 7 had low systemic exposure after oral administration, but high gastrointestinal concentration, as well as good Caco-2 cell permeability. Finally, 7 demonstrated partial efficacy in an IL-12 knock-out mouse model of acute cryptosporidiosis.
biochemistry & molecular biology,parasitology